HeartBeam Inc. (NASDAQ: BEAT) announced it will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss first-quarter results for the period ended March 31, 2026. The company also plans to provide updates on key growth initiatives, including its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection, and artificial intelligence programs.
The call comes as HeartBeam advances its 3D ECG technology, which received FDA clearance for arrhythmia assessment in December 2024 and for 12-lead ECG synthesis software in December 2025. The company's platform is designed to be the first cable-free device capable of collecting ECG signals from three non-coplanar directions and synthesizing them into a standard 12-lead ECG, enabling portable cardiac monitoring outside medical facilities.
This announcement is significant because it signals HeartBeam's progression from regulatory milestones to commercial execution. The limited commercial launch for arrhythmia assessment represents the company's first step toward generating revenue and gaining real-world clinical experience. Additionally, updates on extended-wear patch development and heart attack detection programs highlight HeartBeam's ambition to address multiple cardiac conditions with its technology. The focus on AI programs suggests the company is investing in data analytics to enhance diagnostic capabilities.
Investors and industry observers will be watching for details on adoption rates, reimbursement progress, and competitive positioning. The earnings call will also provide insight into the company's financial health as it scales operations. HeartBeam holds over 20 issued patents related to its technology, providing a moat against competitors.
For more information, visit the company's newsroom at https://nnw.fm/BEAT and the full press release at https://ibn.fm/yN939. The conference call will be accessible via webcast on HeartBeam's investor relations website. The company's cleared indications for use are detailed at https://www.heartbeam.com/indications.
